GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Escalon Medical Corp (OTCPK:ESMC) » Definitions » ROE %

Escalon Medical (Escalon Medical) ROE % : -16.21% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Escalon Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Escalon Medical's annualized net income for the quarter that ended in Dec. 2023 was $-0.30 Mil. Escalon Medical's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $1.88 Mil. Therefore, Escalon Medical's annualized ROE % for the quarter that ended in Dec. 2023 was -16.21%.

The historical rank and industry rank for Escalon Medical's ROE % or its related term are showing as below:

ESMC' s ROE % Range Over the Past 10 Years
Min: -47.02   Med: -10.71   Max: 40.01
Current: 40.01

During the past 13 years, Escalon Medical's highest ROE % was 40.01%. The lowest was -47.02%. And the median was -10.71%.

ESMC's ROE % is ranked better than
98.03% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.29 vs ESMC: 40.01

Escalon Medical ROE % Historical Data

The historical data trend for Escalon Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Escalon Medical ROE % Chart

Escalon Medical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.93 -35.38 -3.50 1.23 26.78

Escalon Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.08 162.11 43.15 -4.36 -16.21

Competitive Comparison of Escalon Medical's ROE %

For the Medical Devices subindustry, Escalon Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Escalon Medical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Escalon Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Escalon Medical's ROE % falls into.



Escalon Medical ROE % Calculation

Escalon Medical's annualized ROE % for the fiscal year that ended in Jun. 2023 is calculated as

ROE %=Net Income (A: Jun. 2023 )/( (Total Stockholders Equity (A: Jun. 2022 )+Total Stockholders Equity (A: Jun. 2023 ))/ count )
=0.457/( (1.478+1.935)/ 2 )
=0.457/1.7065
=26.78 %

Escalon Medical's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-0.304/( (1.914+1.837)/ 2 )
=-0.304/1.8755
=-16.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Escalon Medical  (OTCPK:ESMC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-0.304/1.8755
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.304 / 11.476)*(11.476 / 4.817)*(4.817 / 1.8755)
=Net Margin %*Asset Turnover*Equity Multiplier
=-2.65 %*2.3824*2.5684
=ROA %*Equity Multiplier
=-6.31 %*2.5684
=-16.21 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-0.304/1.8755
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.304 / -0.304) * (-0.304 / -0.284) * (-0.284 / 11.476) * (11.476 / 4.817) * (4.817 / 1.8755)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0704 * -2.47 % * 2.3824 * 2.5684
=-16.21 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Escalon Medical ROE % Related Terms

Thank you for viewing the detailed overview of Escalon Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Escalon Medical (Escalon Medical) Business Description

Traded in Other Exchanges
N/A
Address
435 Devon Park Drive, Suite 824, Wayne, PA, USA, 19087
Escalon Medical Corp operates in the healthcare market specializing in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the area of ophthalmology. Its products are A-Scans, B-Scans, UBM, Pachymeters, Color/Fluorescein Angiography Digital Imaging Systems, Ispan Intraocular Gases, Surgical Packs, Viscous Fluid Transfer Systems, and AXIS Image Management. Substantial revenue is generated from the domestic sales of products.
Executives
David James Jacovini director 120 PINE STREET, PHILADELPHIA PA 19106
John Dogum director 1818 MARKET STREET, 35TH FLOOR, PHILADELPHIA PA 19103
Richard J Depiano director 435 DEVON PARK DRIVE, SUITE 100, WAYNE PA 19087
Lisa A Napolitano director 351 EAST CONESTOGA ROAD, WAYNE PA 19087
C Sean Closkey director 1700 MARKET STREET, 19TH FLOOR, PHILADELPHIA PA 19103
C Todd Trusk director 1410 RUSSELL ROAD, SUITE 100, WAYNE PA 19301
Robert Michael O'connor officer: Chief Financial Officer 53 SORREL RUN, MT. LAUREL NJ 08054
Anthony J Coppola director 1 NORTH NEW YORK ROAD, SMITHVILLE NJ 08205
Federman Jay L Md director 501 N. ESSEX AVENUE, NARBERTH PA 19072
Kwan William L G director 351 EAST CONESTOGA ROAD, WAYNE PA 19087
Mark Wallace officer: Chief Operating Officer 565 E SWEDESFORD ROAD, STE 200, WAYNE PA 19087
Fred G Choate director 601 DELSEA DRIVE, WASHINGTON TOWNSHIP NJ 08080
Depiano Richard J Jr officer: President 575 E. SWEDESFORD ROAD, SUITE 100, WAYNE PA 19087
Berkowitz David officer: Principal Accounting Officer 565 EAST SWEDESFORD ROAD, SUITE 200, WAYNE PA 19087
Mark H Karsch officer: CFO 565 EAST SWEDESFORD ROAD, SUITE 200, WAYNE PA 19087

Escalon Medical (Escalon Medical) Headlines